During the past decade, SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie conducted 12 clinical trials. In the 10-year time frame, 12 clinical trials started and 12 clinical trials were completed, i.e. on average, 100% percent of trials that started reached the finish line to date. In the past 5 years, 6 clinical trials started and 5 clinical trials were completed. i.e. 83.3% of trials that started reached the finish line.

Out of the total clinical trials conducted in "SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie" #1 sponsor was "Hoffmann-La Roche" with 3 trials, followed by "AstraZeneca" with 2 trials sponsored, "Celgene" with 2 trials sponsored, "Gilead Sciences" with 2 trials sponsored and "Janssen Research & Development, LLC" with 2 trials sponsored. Other sponsors include 5 different institutions and companies that sponsored additional 15 trials in total.

In terms of collaborators to trials, out of the total clinical trials conducted in "SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie" #1 collaborator was "Merck Sharp & Dohme LLC" with 3 trials as a collaborator, "Myriad Genetic Laboratories, Inc." with 2 trials as a collaborator, "Eisai Europe Ltd. (United Kingdom)" with 1 trials as a collaborator, "European Network of Gynaecological Oncological Trial Groups (ENGOT)" with 1 trials as a collaborator and "GOG Foundation" with 1 trials as a collaborator. Other collaborators include -2 different institutions and companies that were collaborators in the rest 8 trials.

According to Clinical.Site data, the most researched conditions in "SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie" are "Indolent Non-Hodgkin's Lymphomas" (2 trials), "Myelodysplastic Syndromes" (2 trials), "Advanced Ovarian Cancer" (1 trials), "Anaplastic Large-cell Lymphoma" (1 trials) and "BRCA Mutated" (1 trials). Many other conditions were trialed in "SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie" in a lesser frequency.

Most popular intervention types in "SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie" are "Drug" (21 trials) and "Other" (1 trials). Other intervention types were less common.

The name of intervention was led by "Placebo" (6 trials), "Rituximab" (4 trials), "Capecitabine" (2 trials), "Durvalumab" (2 trials) and "Fluorouracil (5-FU)" (2 trials). Other intervention names were less common.

The vast majority of trials in "SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie" are 18 trials for "All" genders and 3 trials for "Female" genders.

Currently, there are NaN active trials in "SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie". undefined are not yet recruiting, 6 are recruiting, 6 are Active, not recruiting, and undefined are Enrolling by invitation. In total, there were 4 completed trials in SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie, undefined suspended trials, and 5 terminated clinical trials to date.

Out of the total trials that were conducted in SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie, 1 "Phase 1" clinical trials were conducted, 8 "Phase 2" clinical trials and 15 "Phase 3" clinical trials were conducted as well. "Phase 4" trials included 1 trials, and there were also 0 trials that are defined as “Not Applicable".

SPZOZ MSW zWarmińsko-MazurskimCen.Onko.wOlsztynie has several departments that took part in Clinical trials: "Oddzial Kliniczny Hematologii SPZOZ MSWiA z Warminsko-Mazurskim Centrum Onkologii w Olsztynie" - 4 trials